A measure derived from heart and lung imaging data can predict the long-term risk of death for people with newly diagnosed pulmonary arterial hypertension (PAH), a study found. The measure, called FAC/PASP, was better at predicting long-term death rates than a more established measure, TAPSE/PASP, the study showed. Both measures are…
News
Chronic kidney disease (CKD) is common among people newly diagnosed with pulmonary hypertension (PH), and patients face an increased risk of developing CKD — marked by worsening kidney function over time — as the condition progresses, according to a new study. The researchers found that certain blood flow measures,…
People with severe pulmonary arterial hypertension (PAH) who respond well to early treatment with prostacyclin infusions may be able to reduce or stop the treatment, a study suggested. In a long-term analysis of 101 patients, about one in five achieved enough improvement in heart and lung blood flow measurements…
In China, Volibris (ambrisentan, sold as Letairis and generics in the U.S.) may have advantages over similar medications for pulmonary arterial hypertension (PAH) when considering factors including safety, efficacy, and economic value. That’s according to a study in which a team of experts developed a multi-criteria decision analysis…
Restoring the levels of BMP3, a naturally occurring protein involved in cell communication that regulates pulmonary blood vessels, reversed key features of pulmonary arterial hypertension (PAH) in preclinical models, a study found. Compared with people without PAH, levels of BMP3 were lower in lung tissue, smooth muscle cells that…
A novel score calculated based on markers of liver and heart health may help to predict the risk of future clinical worsening in people with pulmonary arterial hypertension (PAH), according to a new study. “This study utilized routine [tests] to estimate [blood flow] parameters and established a novel hepatic-cardiac…
The U.S. Food and Drug Administration (FDA) has cleared a noninvasive add-on feature for a test that detects heart patterns in people with pulmonary hypertension (PH). The new tool in the Corvista-PH test estimates the likelihood of elevated pulmonary capillary wedge pressure (PCWP), a key marker of heart failure. The…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IKT-001, an experimental formulation of imatinib that Inhibikase Therapeutics is developing to treat pulmonary arterial hypertension (PAH). The FDA gives orphan drug designation to investigational medications that aim to treat rare diseases, defined as conditions…
COVID-19 and pulmonary arterial hypertension (PAH) may share molecular mechanisms that could explain common disease-related features, a study reported. According to researchers, the findings provide a framework for exploring disease mechanisms and prioritizing future therapeutic strategies that target overlapping mechanisms of both conditions. The study, “Network-Based Multiomics Integration…
People with pulmonary arterial hypertension (PAH) have less diversity among the viruses that infect bacteria in their digestive tracts, according to a new study. These findings add to a growing body of research suggesting that the gut microbiome — the community of bacteria, viruses, and other microscopic organisms…
Once-daily use of Insmed‘s experimental inhaled treatment TPIP — fully, treprostinil palmitil inhalation powder — showed a range of benefits over one year in people with pulmonary arterial hypertension (PAH), a rare condition in which the blood vessels supplying the lungs become narrowed. That’s according to new 12-month…
Respiratory rehabilitation is safe and can help improve exercise capacity in people with chronic obstructive pulmonary disease (COPD) with or without pulmonary hypertension (PH), a study reported. A rehab program “demonstrated effectiveness in improving [exercise capacity] for COPD patients, regardless of the echocardiographic probability of PH,” the researchers…
